Because EpCAM and CD133 are well-accepted surface markers in HCC [34, 35], we further analyzed the EpCAM and CD133 expression to study their potential roles during HCC carcinogenetic transformation in NASH-HCC mice. The gene discussed is EPCAM; the disease is metabolic dysfunction-associated steatohepatitis.